Navigation Links
Lilly and Incyte Announce Baricitinib Efficacy and Safety Data from the Open-Label, Long-Term Extension of the Phase 2b JADA Study in Patients with Rheumatoid Arthritis
Date:6/13/2013

tal Sciences in the Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences at the University of Oxford, and steering committee member for the study.

A copy of the EULAR oral presentation can be accessed at:  2013 EULAR - JADA 52-Week Presentation  

Trial DesignThis randomized, open-label, long-term extension of Phase 2b JADA study included 201 (95 percent) of the eligible 212 patients. Of the 201 patients, 184 completed 52 weeks of treatment, 15 discontinued treatment, and two patients had not yet completed the full 52 weeks of treatment. Patients received either 4 mg or 8 mg once-daily doses of baricitinib beginning at week 24 through week 52.

In the initial 12-week treatment duration, patients received one of four doses of baricitinib (1 mg, 2 mg, 4 mg or 8 mg) or placebo, administered once daily. In the 12- to 24-week portion of the study, patients initially randomized to placebo or the 1 mg baricitinib dose were re-randomized to receive either 4 mg once daily or 2 mg twice daily for an additional 12 weeks; patients initially randomized to the 2 mg, 4 mg and 8 mg doses continued therapy with those doses.

Patients who completed week 24 were eligible to receive either the 4- or 8-mg once daily dose through week 52. The study is ongoing, with all patients who are continuing in the study receiving baricitinib 4 mg once daily.

About JAK InhibitionThere are four known JAK enzymes: JAK1, JAK2, JAK3 and TYK2.[3] These enzymes are critical components of signaling mechanisms used by a number of cytokines and growth factors, including several that are elevated in patients with RA. Cytokines such as interleukin-6, -12 and -23 and both type 1 and type 2 interferons signal through these pathways. JAK-dependent cytokines have been implicated in the pathogenesis of a number of inflammatory and autoi
'/>"/>

SOURCE Eli Lilly and Company; Incyte Corporation
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Lilly to Present at Goldman Sachs Global Healthcare Conference
2. Lilly Acquires Novel Tau Tangle Diagnostic Program to Bolster Alzheimers Disease Research and Development
3. Lilly and Incyte Announce Additional Phase IIb Baricitinib Data, Including MRI Results, in Patients with Rheumatoid Arthritis
4. SHAREHOLDER ALERT: The Law Firm of Levi & Korsinsky Notifies Investors with Losses on Their Investment in Incyte Corporation of Class Action Lawsuit and the May 6, 2013 Lead Plaintiff Deadline
5. Todays Research on Incyte and Arena Pharma: Biotech Stocks Up on Drug Approvals
6. Steep Hill Laboratories and Halent Scientific Proudly Announce Historic Merger
7. Andain Inc. Announces 2,000 Units Initial Production of the Breakthrough Miniature Disposable Insulin Pump for Use in Clinical Trials for Type-I and Type-II Diabetes
8. Verenium Announces Appointment Of Brian Carter As Vice President Of Grain Processing
9. Neogen announces Bohannon retirement, successor named
10. BioDelivery Sciences Announces NDA Submission for BUNAVAIL on Track Following Positive Pre-NDA Meeting with FDA
11. Hemostemix Announces Formation of Scientific Advisory Board
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/31/2014)... This is a professional and in-depth ... The report provides basic biocides information, including its ... well as industry overview. This research covers the ... well as Global industry analysis covering macroeconomic environment ... Chinese biocides industry covers information on ...
(Date:10/31/2014)... ENVIRON , an international ... that Dr. Harvey Clewell III has rejoined the ... closely with senior professionals in ENVIRON’s Health Sciences ... at The Hamner Institutes for Health Sciences (The ... he is Director, Center for Human Health Assessment. ...
(Date:10/31/2014)... , Oct. 31, 2014  Atlanta-based Intellimedix could ... accompanying the onset of Ebola by suggesting a ... at Georgia Tech,s Center for Computational Systems Biology ... to find alternative uses for existing drugs through ... to aid the bout against Ebola. ...
(Date:10/30/2014)... 30, 2014  Ardelyx, Inc. (NASDAQ: ... cardio-renal, gastrointestinal and metabolic diseases, today announced that ... on Thursday, November 6, 2014. Following the announcement, ... conference call and webcast at 4:30pm ET to ... business update. The live webcast can ...
Breaking Biology Technology:Biocides Market for International & Chinese Regional Development Analysis Now Available at DeepResearchReports.com 2Biocides Market for International & Chinese Regional Development Analysis Now Available at DeepResearchReports.com 3Internationally recognized health scientist Dr. Harvey Clewell renews association with ENVIRON 2Internationally recognized health scientist Dr. Harvey Clewell renews association with ENVIRON 3Atlanta-Based Intellimedix May Help Solve Ebola With Computer Algorithms 2Ardelyx to Report Third Quarter 2014 Financial Results on November 6, 2014 2
... , , , , ... CA and Ottawa, Ontario), a clinical stage biopharmaceutical company developing a ... the Second and final closing of a private placement financing with ... $5 million. , , As previously reported, ...
... CINCINNATI, Sept. 18 LCA-Vision Inc. (Nasdaq: LCAV ... the Lasik Plus (R) brand, announces that Steven C. Straus ... the company,s board of directors effective September 25, 2009 to ... Management of daily operations will be the responsibility of Chief ...
... 18 Omeros Corporation today announced the launch of its ... stock. Omeros is a clinical-stage biopharmaceutical company committed to ... of the central nervous system. , , ... $10.00 to $12.00 per share. Omeros has applied to ...
Cached Biology Technology:Jennerex Completes Over-Subscribed Series C Financing for Aggregate Gross Proceeds of Over $5.5 Million 2Jennerex Completes Over-Subscribed Series C Financing for Aggregate Gross Proceeds of Over $5.5 Million 3LCA-Vision Announces CEO Resignation 2Omeros Commences Initial Public Offering of Common Stock 2Omeros Commences Initial Public Offering of Common Stock 3
(Date:10/29/2014)... hair as a consequence of chemotherapy will benefit from ... cooling technology that prevents hair loss. , The research ... global scalp cooling manufacturing company, Paxman Coolers, of Fenay ... the University of Huddersfield. , The research will be ... background in the pharmacology of cancer treatment, which he ...
(Date:10/29/2014)... for the Society of Interventional Radiology,s (SIR) ... the one place where interventional radiologists, diagnostic ... professionals can come together to find the ... presented, discussed and tested. , "Connecting ... medicine, SIR 2015 will feature essential updates ...
(Date:10/29/2014)... industrial products are in the environment – and hundreds ... scientists have yet to determine whether they cause health ... that by estimating which substances people are exposed to ... ACS journal Environmental Science & Technology . , ... to human health of any given substance depend primarily ...
Breaking Biology News(10 mins):New technology on the way to aid cancer suffers who lose their hair after chemotherapy 2SIR 2015: Interventional radiology shapes tomorrow's medicine 2
... University, the team mapped the presence of foxes in ... their likely distribution as a blueprint for fox eradication, ... of Canberra professor in wildlife genetics and leader of ... northern and eastern Tasmania and the model developed by ...
... CA Researchers from the Carnegie Institution are rolling out ... AToMS, for the first time at the American Geophysical ... and its scientific observations are uncovering a previously invisible ... is helping researchers look at the world in a ...
... MA and SAN FRANCISCO, CADecember 4, 2012 The ALS ... today announced the formation of a research collaboration to ... the preclinical drug development process. "We are ... ALS therapeutic development," said Steve Perrin, PhD, CEO and ...
Cached Biology News:Fox invasion threatens wave of extinction, UC research finds 2Carnegie debuts revolutionary biosphere mapping capability at AGU 2Carnegie debuts revolutionary biosphere mapping capability at AGU 3ALS TDI and Gladstone Institutes collaborate to discover potential ALS treatments 2
Bio-Plex Manager software, version 3.0, 5 license netshare, is a five-user software package that provides access to data from the Bio-Plex suspension array system from a server. This version does not...
... 3 x 3 nmol (individual) with ... 3 siRNAs specifically targeted to your target gene ... reagent guarantees you get more than 75% knockdown ... conditions (100 nM siRNA for transfection and confirmation ...
... siTrio siRNA --- a cocktail of 3 ... of interestis our most popular product. The ... 75% knockdown of your target gene when ... for transfection and confirmation of optimal transfection ...
... IDS 25-Hydroxy Vitamin D kit is ... determination of 25-hydroxyvitamin D (25-OH D) ... serum or plasma. Our patented DIRECT ... solvent precipitation and centrifugation and therefore ...
Biology Products: